Earnings call transcript: BeOne Medicines sees strong Q1 2026 growth

BeOne Medicines delivered a strong Q1 2026 with product revenue up 34% year over year to $1.5 billion, led by BRUKINSA sales of $1.1 billion (+38%) and U.S. sales of $761 million. Gross margin improved to 89% from 85%, net income reached $227 million, and the company raised full-year revenue guidance to $6.3 billion-$6.5 billion, $100 million above prior targets. Management also highlighted continued pipeline progress across hematology and solid tumors, including upcoming clinical and regulatory catalysts.

Analysis

This print is not just a beat; it is a proof point that the company has crossed an inflection from “single-asset story” to durable platform compounder. The most important second-order effect is that BRUKINSA’s volume-led momentum, combined with margin expansion, gives management flexibility to fund a more aggressive pipeline without jeopardizing operating leverage. That matters because the market usually discounts China-origin biotech names on binary regulatory risk, but this quarter shows the business is increasingly self-financing and less dependent on capital markets.

The competitive message is also sharper than the headline suggests: the company is using long-duration efficacy data to defend share while competitors are still fighting over short follow-up windows. That should pressure alternative BTK narratives and likely cap enthusiasm around newer entrants whose differentiation is not yet mature. The bigger strategic read-through is that a successful next wave of launches in BCL-2 and BTK degradation could turn the current hematology franchise into a three-legged stool, reducing reliance on any one product and increasing the odds of a higher terminal multiple.

The main risk is that the current upgrade cycle is front-loaded with optimism while near-term reimbursement, sequencing, and label-expansion execution remain unproven. The stock can stay strong for months if ASCO/EHA and regulatory milestones land cleanly, but any stumble in readouts or a slower-than-expected launch ramp in the U.S./Europe would likely compress the multiple quickly because expectations are now rising faster than the evidence base. The market is probably underpricing how much of the 2026 guidance raise is “quality” versus one-offs, but it may also be overestimating how immediately new assets can contribute.

Key Decisions for Investors

• Maintain/add long ONC on pullbacks over the next 1-3 weeks into ASCO/EHA, with a 3-6 month horizon; thesis is operating leverage plus multiple expansion as pipeline de-risks. Use a tight stop if event data disappoints.
• Relative value: long ONC / short ABBV for 2-4 months. ONC has improving growth visibility and re-acceleration optionality, while ABBV faces more mature portfolio pressure and weaker incremental catalyst density.
• Buy ONC call spreads expiring after ASCO/EHA catalysts. Favor upside convexity because the market is likely to re-rate on pipeline breadth, but headline risk is high if any late-stage readout is softer than implied.
• Short a basket of BTK-franchise laggards versus ONC over 1-2 quarters. The key trade is not generic biotech beta; it is share capture from a data-differentiated incumbent versus shorter-follow-up competitors.
• If the stock gaps on guidance and conference momentum, take partial profits rather than full exit; the balance sheet and self-funding profile support a multi-quarter re-rating, but event-driven volatility should be expected.